Pegaspargase (marketed as Oncaspar), a biologic drug approved by the FDA in 2006 for acute lymphoblastic leukemia (ALL) as a component of multi-agent chemotherapy, has long gone unchallenged by biosimilar candidates. That could soon change, according to information recently reported by the Generics and Biosimilars Initiative (GaBI).
Pegaspargase (marketed as Oncaspar), a biologic drug approved by the FDA in 2006 for acute lymphoblastic leukemia (ALL) as a component of multi-agent chemotherapy, has long gone unchallenged by biosimilar candidates. That could soon change, according to information recently reported by the Generics and Biosimilars Initiative (GaBI).
The drug, according to GaBI, has historic annual sales of approximately $1 billion. As its patents were licensed to Sigma Tau in 1994 (later acquired by Baxalta, then subsequently acquired by Shire), the industry estimates that the drug would have lost its US patent protection in 2006.
Despite pegaspargase’s potential for high returns, biosimilar manufacturers focused on products like adalimumab, infliximab, and trastuzumab have not historically challenged the high-earning drug. Yet several biosimilar manufactures may be ready to take on the high costs and complex development challenges of developing products referenced on this treatment:
Given the fact that each of these biosimilar manufactures is in early stages of development with candidates referencing Oncaspar, Shire will no doubt see continued strong earnings from this therapy as biopharmaceutical developers race to bring its first biosimilar to market.
Biosimilar Substitution Can Reduce TCOC, Improve Provider Performance in Value-Based Payment Models
December 7th 2023A simulation study estimated the impact of biosimilar substitution on total cost of care (TCOC) and provider financial performance in the final performance period of the Oncology Care Model.
Study Documents HCPs’ Experiences of a Mandatory Switch to Inform Future Transitions
December 2nd 2023A survey explores the experiences of health care providers (HCP) in New Zealand throughout the transition process following a mandatory switch from the adalimumab originator (Humira) to a biosimilar in 2022.